Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Otilia Husu

Physician Assistant Goodyear, AZ Physician Assistant

NPI 1194995951 CMS profile 11059395

3030 N Litchfield Rd Ste 110, Goodyear, AZ 85395

Open in the dashboard

General payments

$4,329

145 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Otilia Husu of Goodyear, AZ is reported in the CMS Open Payments database as having received $4,329 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,445 42
2024 General $1,198 38
2023 General $765 36
2022 General $695 25
2021 General $226 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Otilia Husu
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Otilia Husu were reported at $1,445. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Otilia Husu Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $226 $132 $37–$438 $132
2022 $695 $155 $48–$522 $149
2023 $765 $167 $52–$557 $160
2024 $1,198 $178 $55–$600 $164
2025 $1,445 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,087 44 payments
  2. Lilly USA, LLC $645 39 payments
  3. Novo Nordisk Inc $419 15 payments
  4. AbbVie, Inc. $286 15 payments
  5. Abbott Laboratories $181 6 payments
  6. Inspire Medical Systems, Inc. $145 1 payment
  7. GlaxoSmithKline, LLC. $121 7 payments
  8. Boston Scientific Corporation $112 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $91 5 payments
  10. Astellas Pharma US Inc $77 3 payments
  11. Other $164 9 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,329 145 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $1,035 25 payments
  2. BREZTRI $757 13 payments
  3. AIRSUPRA $621 11 payments
  4. MOUNJARO $518 28 payments
  5. Ozempic $372 13 payments
  6. UBRELVY $256 13 payments
  7. RYBELSUS $222 10 payments
  8. INSPIRE $145 1 payment
  9. SYNTHROID $134 7 payments
  10. JARDIANCE $114 9 payments
  11. Other $1,028 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

2,585

Median for Physician Assistant: 241

Drug cost

$121,831

Median for Physician Assistant: $4,110

Branded share of claims

18.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 25 $28,295
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $18,888
Ozempic Semaglutide Brand 22 $18,465
Eliquis Apixaban Brand 17 $16,982
Farxiga Dapagliflozin Propanediol Brand 13 $10,304
Synthroid Levothyroxine Sodium Brand 50 $2,438
Albuterol Sulfate Hfa Albuterol Sulfate Brand 76 $2,083
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 16 $1,860
Gabapentin Generic 76 $1,506
Atorvastatin Calcium Generic 203 $1,349

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $333
$333 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $320
$320 13 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $181
$181 — —
MOUNJARO
  • Lilly USA, LLC $89
$89 25 —
JARDIANCE
  • Lilly USA, LLC $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record